Verona Pharma (VRP)

 

Latest News

Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment Dose escalation trial will evaluate RPL554 in approximately 400 COPD patients LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on...

Verona nears Phase 2b clinical trial for RPL554

Verona Pharma announces regulatory approval in five European countries for a Phase 2b dose-ranging trial of RPL554 fo...

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:V...

Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs

Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces the...

All News

DateHeadlineSource
26-07-17Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentRNS
27-06-17Verona nears Phase 2b clinical trial for RPL554StockMarketWire
27-06-17Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across EuropeRNS
22-06-17Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory AffairsRNS
06-06-17Verona Pharma plc : Holding(s) in CompanyRNS
06-06-17Verona Pharma plc : Holding(s) in CompanyRNS
05-06-17Verona initiates US clinical pharmacokinetic study for RPL554StockMarketWire
05-06-17Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDARNS
30-05-17Holding(s) in CompanyRNS
30-05-17Holding(s) in CompanyRNS
25-05-17Holding(s) in CompanyRNS
25-05-17Verona Pharma Announces Further Exercise of Over-Allotment Option and Resulting Total Voting RightsRNS
23-05-17Verona CEO to present at Jefferies Healthcare ConferenceStockMarketWire
23-05-17Verona Pharma to Present at Jefferies 2017 Global Healthcare ConferenceRNS
23-05-17Holding(s) in CompanyRNS
22-05-17Broker Forecast - Jefferies International issues a broker note on Verona Pharma PLCStockMarketWire
16-05-17Partial Exercise of Over-Allotment OptionRNS
08-05-17Holding(s) in CompanyRNS
05-05-17Holding(s) in CompanyRNS
05-05-17Holding(s) in CompanyRNS
05-05-17Holding(s) in CompanyRNS
03-05-17Holding(s) in CompanyRNS
03-05-17Block Listing Application and ReviewRNS
03-05-17Grant of Options and RSUs and PDMR DealingsRNS
02-05-17Closing of Global Offering and Total Voting RightsRNS
02-05-17Director/PDMR ShareholdingRNS
28-04-17Director Deals - Verona Pharma PLC (VRP)StockMarketWire
28-04-17Director/PDMR ShareholdingRNS
27-04-17Pricing of Offering and Approval to List on NASDAQRNS
19-04-17Global Offering and Application to List on NASDAQRNS
18-04-17FDA authorises start of Verona Pharma's US trialStockMarketWire
18-04-17FDA Authorisation to Proceed RPL554 InvestigationRNS
12-04-17All resolutions passed at Verona AGMStockMarketWire
12-04-17Result of AGMRNS
04-04-17Files Statement for Proposed Global OfferingRNS
04-04-17Files Statement for Proposed Global OfferingRNS
04-04-171st Patient Dosed in Ph2a Trial for RPL554 in CFRNS
03-04-17Board ChangeRNS
31-03-17COPD Collaboration and New Commercial DirectorRNS
22-03-17Verona Pharma in services agreement with QuintilesIMSStockMarketWire

RSS feeds

  • Editorial news feed for LSE:VRP Editorial
  • Regulatory news feed for LSE:VRP Regulatory